source
- Kailera's oral GLP-1 pill shows ~10% weight loss in Chinese Phase 3 trialKailera Therapeutics reported that its oral GLP-1 candidate HRS-7535 achieved about 10% average weight loss over 44 weeks in a Phase 3 study in China. The highest daily dose led to a mean 9.8% red…
- Fresenius Kabi issues correction for Ivenix infusion pumps over battery health software bugThe U.S. Food and Drug Administration has classified a correction for Fresenius Kabi’s Ivenix Large Volume infusion pump as the most serious type of recall. The action does not require removal of t…